Scios/Wyeth-Ayerst Fiblast agreement calls for $12 mil. up-front to Scios.
Executive Summary
SCIOS/WYETH-AYERST FIBLAST AGREEMENT INCLUDES $12 MIL. UP FRONT cash payment from Wyeth-Ayerst, the companies announced Oct. 23. The joint development and commercialization agreement for Scios' trafermin (basic fibroblast growth factor) for the treatment of neurological and cardiovascular disorders will also include up to $32 mil. in milestone payments to Scios and a $12 mil. credit line from Wyeth-Ayerst to fund expansion of the Fiblast manufacturing facility.